Cold shock domain-containing protein E1 is a posttranscriptional regulator of the LDL receptor
| Autor: | Smith, Geoffrey A, Padmanabhan, Arun, Lau, Bryan H, Pampana, Akhil, Li, Li, Lee, Clara Y, Pelonero, Angelo, Nishino, Tomohiro, Sadagopan, Nandhini, Xia, Vivian Q, Jain, Rajan, Natarajan, Pradeep, Wu, Roland S, Black, Brian L, Srivastava, Deepak, Shokat, Kevan M, Chorba, John S |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Cold-Shock Response
Messenger RNA-Binding Proteins Biological Sciences Cardiovascular Atherosclerosis Medical and Health Sciences LDL DNA-Binding Proteins Mice Heart Disease Genetic Receptors Genetics Animals Humans RNA 2.1 Biological and endogenous factors Proprotein Convertase 9 Aetiology Digestive Diseases Transcription Heart Disease - Coronary Heart Disease Biotechnology |
| Zdroj: | Science translational medicine, vol 14, iss 662 |
| Popis: | The low-density lipoprotein receptor (LDLR) controls cellular delivery of cholesterol and clears LDL from the bloodstream, protecting against atherosclerotic heart disease, the leading cause of death in the United States. We therefore sought to identify regulators of the LDLR beyond the targets of current therapies and known causes of familial hypercholesterolemia. We found that cold shock domain-containing protein E1 (CSDE1) enhanced hepatic LDLR messenger RNA (mRNA) decay via its 3' untranslated region and regulated atherogenic lipoproteins in vivo. Using parallel phenotypic genome-wide CRISPR interference screens in a tissue culture model, we identified 40 specific regulators of the LDLR that were not previously identified by observational human genetic studies. Among these, we demonstrated that, in HepG2 cells, CSDE1 regulated the LDLR at least as strongly as statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. In addition, we showed that hepatic gene silencing of Csde1 treated diet-induced dyslipidemia in mice to a similar degree as Pcsk9 silencing. These results suggest the therapeutic potential of targeting CSDE1 to manipulate the posttranscriptional regulation of the LDLR mRNA for the prevention of cardiovascular disease. Our approach of modeling a clinically relevant phenotype in a forward genetic screen, followed by mechanistic pharmacologic dissection and in vivo validation, may serve as a generalizable template for the identification of therapeutic targets in other human disease states. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|